Acadian Asset Management LLC Invests $3.46 Million in DexCom, Inc. (DXCM)

Acadian Asset Management LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 24,188 shares of the medical device company’s stock, valued at approximately $3,459,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System boosted its holdings in shares of DexCom by 0.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 120,747 shares of the medical device company’s stock valued at $11,469,000 after acquiring an additional 470 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of DexCom by 9.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,552 shares of the medical device company’s stock valued at $527,000 after acquiring an additional 471 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its holdings in shares of DexCom by 7.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 6,879 shares of the medical device company’s stock valued at $653,000 after acquiring an additional 486 shares in the last quarter. Xact Kapitalforvaltning AB boosted its holdings in shares of DexCom by 4.1% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 12,700 shares of the medical device company’s stock valued at $1,206,000 after acquiring an additional 500 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in shares of DexCom by 23.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 3,282 shares of the medical device company’s stock valued at $469,000 after acquiring an additional 630 shares in the last quarter.

In other news, VP Patrick Michael Murphy sold 2,372 shares of DexCom stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $143.69, for a total value of $340,832.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark G. Foletta sold 1,000 shares of DexCom stock in a transaction dated Friday, August 24th. The stock was sold at an average price of $137.50, for a total value of $137,500.00. Following the completion of the transaction, the director now directly owns 4,052 shares of the company’s stock, valued at $557,150. The disclosure for this sale can be found here. Over the last three months, insiders sold 157,892 shares of company stock valued at $21,864,030. Corporate insiders own 1.80% of the company’s stock.

DXCM stock opened at $149.46 on Friday. DexCom, Inc. has a 1-year low of $49.80 and a 1-year high of $152.14. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62. The stock has a market capitalization of $11.74 billion, a PE ratio of -257.69 and a beta of 0.60.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.29. DexCom had a negative return on equity of 3.08% and a net margin of 4.72%. The firm had revenue of $266.70 million during the quarter, compared to analyst estimates of $242.72 million. The firm’s revenue for the quarter was up 44.5% on a year-over-year basis. Analysts expect that DexCom, Inc. will post -0.49 earnings per share for the current year.

Several research firms recently weighed in on DXCM. Morgan Stanley raised their price objective on DexCom from $130.00 to $150.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. Oppenheimer set a $125.00 target price on DexCom and gave the stock a “buy” rating in a report on Thursday, August 2nd. Piper Jaffray Companies lifted their target price on DexCom to $150.00 and gave the stock an “overweight” rating in a report on Thursday, August 2nd. Bank of America lifted their target price on DexCom from $106.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. Finally, Berenberg Bank raised DexCom from a “hold” rating to a “buy” rating and set a $140.00 target price on the stock in a report on Monday, August 6th. Seven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. DexCom currently has an average rating of “Buy” and an average price target of $132.50.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/11/10/acadian-asset-management-llc-invests-3-46-million-in-dexcom-inc-dxcm.html.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Bull Market

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply